Qualitative detection of promotor hypermethylation of 2 cervical cancer associated genes (FAM19A4 and hsa-miR124-2).

Identify HPV positive women with high short-term progression to (pre)cancer.

Special Features:

  • Sample types:
    • Bisulfite-converted DNA isolated from physician collected cervical specimens or self-collected vaginal specimens
  • Clinical performance - Long-term data:   
    • Most evaluated and validated methylation assay to identify HPV positive women with progressing cervical disease in direct need for colposcopy or other follow-up procedures1,2
    • Demonstrating very high sensitivity for cervical cancer detection (95.0-100%) in HPV-positive cervical specimens2,3,4
    • Longitudinal data: The long-term risk for cancer with a negative PreCursor-M+ is lower than with a negative cytology result; for CIN3 the long-term risk is similar as cytology5,6 
  • Flexible:
    • Suitable for various sample types, including self-samples and common Liquid Based Cytology media types
    • Compatible with standard DNA extraction methods
  • Reliable:     
    • Build-in check for sample quality ensuring reliable results 

Precursor-M+ is a registered trademark of the legal manufacturer, Self-screen B.V., the Netherlands, and is distributed by Fujirebio Europe.

CE marked

Product number 81352

72 Tests
Please contact your local Fujirebio representative for the availability of this product in your country.

Click here to navigate

  • Details
  • Conditions of sale
  • Documentation
  • Insights
  • Related products